KBC Group NV raised its position in Thermo Fisher Scientific Inc. (NYSE:TMO) by 97.3% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 295,358 shares of the medical research company’s stock after acquiring an additional 145,687 shares during the quarter. KBC Group NV’s holdings in Thermo Fisher Scientific were worth $56,083,000 at the end of the most recent quarter.

Other hedge funds have also recently bought and sold shares of the company. Bank of Nova Scotia Trust Co. bought a new position in Thermo Fisher Scientific in the third quarter valued at about $106,000. Ropes Wealth Advisors LLC lifted its holdings in Thermo Fisher Scientific by 15.8% in the second quarter. Ropes Wealth Advisors LLC now owns 710 shares of the medical research company’s stock valued at $124,000 after acquiring an additional 97 shares during the period. Atlantic Trust LLC bought a new position in Thermo Fisher Scientific in the second quarter valued at about $138,000. Acrospire Investment Management LLC lifted its holdings in Thermo Fisher Scientific by 66.7% in the second quarter. Acrospire Investment Management LLC now owns 1,000 shares of the medical research company’s stock valued at $174,000 after acquiring an additional 400 shares during the period. Finally, SeaCrest Wealth Management LLC bought a new position in Thermo Fisher Scientific in the fourth quarter valued at about $195,000. 86.31% of the stock is currently owned by institutional investors.

Shares of Thermo Fisher Scientific Inc. (TMO) opened at $200.18 on Friday. The company has a debt-to-equity ratio of 0.74, a quick ratio of 0.92 and a current ratio of 1.35. Thermo Fisher Scientific Inc. has a 1 year low of $151.74 and a 1 year high of $226.44. The stock has a market capitalization of $80,271.17, a PE ratio of 21.12, a P/E/G ratio of 1.47 and a beta of 1.11.

Thermo Fisher Scientific (NYSE:TMO) last released its earnings results on Wednesday, January 31st. The medical research company reported $2.79 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.66 by $0.13. Thermo Fisher Scientific had a return on equity of 16.01% and a net margin of 10.64%. The firm had revenue of $6.05 billion during the quarter, compared to analysts’ expectations of $5.72 billion. During the same quarter last year, the business posted $2.41 earnings per share. The firm’s revenue was up 22.1% on a year-over-year basis. analysts forecast that Thermo Fisher Scientific Inc. will post 10.81 EPS for the current fiscal year.

The firm also recently announced a quarterly dividend, which will be paid on Monday, April 16th. Investors of record on Thursday, March 15th will be given a dividend of $0.17 per share. The ex-dividend date is Wednesday, March 14th. This represents a $0.68 annualized dividend and a dividend yield of 0.34%. This is a boost from Thermo Fisher Scientific’s previous quarterly dividend of $0.15. Thermo Fisher Scientific’s dividend payout ratio (DPR) is currently 10.71%.

In related news, CFO Stephen Williamson sold 5,000 shares of the stock in a transaction dated Wednesday, February 7th. The stock was sold at an average price of $209.26, for a total transaction of $1,046,300.00. Following the completion of the sale, the chief financial officer now owns 30,741 shares in the company, valued at $6,432,861.66. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, SVP Gregory J. Herrema sold 33,327 shares of the stock in a transaction dated Friday, February 2nd. The stock was sold at an average price of $219.70, for a total value of $7,321,941.90. Following the sale, the senior vice president now owns 60,471 shares of the company’s stock, valued at approximately $13,285,478.70. The disclosure for this sale can be found here. Insiders have sold 144,327 shares of company stock valued at $28,680,042 in the last quarter. 0.49% of the stock is currently owned by company insiders.

A number of analysts have commented on the company. ValuEngine upgraded Thermo Fisher Scientific from a “hold” rating to a “buy” rating in a research report on Friday, February 2nd. Bank of America upped their price target on Thermo Fisher Scientific from $235.00 to $250.00 and gave the stock a “buy” rating in a research report on Thursday, February 1st. Morgan Stanley upped their price target on Thermo Fisher Scientific from $223.00 to $227.00 and gave the stock an “overweight” rating in a research report on Thursday, February 1st. Barclays upped their price target on Thermo Fisher Scientific from $225.00 to $245.00 and gave the stock an “overweight” rating in a research report on Thursday, February 1st. Finally, Leerink Swann restated an “outperform” rating and issued a $239.00 price target (up previously from $200.00) on shares of Thermo Fisher Scientific in a research report on Thursday, February 1st. They noted that the move was a valuation call. Two investment analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average target price of $220.50.

TRADEMARK VIOLATION NOTICE: “KBC Group NV Purchases 145,687 Shares of Thermo Fisher Scientific Inc. (TMO)” was first reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this report on another website, it was illegally stolen and reposted in violation of U.S. and international copyright & trademark law. The legal version of this report can be accessed at https://www.thecerbatgem.com/2018/02/11/kbc-group-nv-purchases-145687-shares-of-thermo-fisher-scientific-inc-tmo.html.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc develops, manufactures and sells a range of products. The Company provides analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO).

Institutional Ownership by Quarter for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.